S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:CLPT

ClearPoint Neuro (CLPT) Stock Price, News & Analysis

$6.80
+0.08 (+1.19%)
(As of 03/28/2024 ET)
Today's Range
$6.66
$6.92
50-Day Range
$6.03
$7.86
52-Week Range
$4.05
$10.95
Volume
84,050 shs
Average Volume
266,496 shs
Market Capitalization
$183.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

ClearPoint Neuro MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
76.5% Upside
$12.00 Price Target
Short Interest
Bearish
5.19% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.69mentions of ClearPoint Neuro in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.75) to ($0.71) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.17 out of 5 stars

Medical Sector

789th out of 939 stocks

Surgical & Medical Instruments Industry

86th out of 97 stocks

CLPT stock logo

About ClearPoint Neuro Stock (NASDAQ:CLPT)

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

CLPT Stock Price History

CLPT Stock News Headlines

ClearPoint Neuro (NASDAQ:CLPT) Trading Down 3%
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Earnings Outlook For ClearPoint Neuro
The Top 7 Under-$15 Stocks to Buy in March 2024
ClearPoint Neuro, Inc. (CLPT)
See More Headlines
Receive CLPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ClearPoint Neuro and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/29/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:CLPT
Employees
107
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$15.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+76.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-22,090,000.00
Pretax Margin
-92.21%

Debt

Sales & Book Value

Annual Sales
$23.96 million
Book Value
$0.86 per share

Miscellaneous

Free Float
25,417,000
Market Cap
$183.44 million
Optionable
Optionable
Beta
0.89
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

CLPT Stock Analysis - Frequently Asked Questions

Should I buy or sell ClearPoint Neuro stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ClearPoint Neuro in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLPT shares.
View CLPT analyst ratings
or view top-rated stocks.

What is ClearPoint Neuro's stock price target for 2024?

3 brokers have issued 1 year target prices for ClearPoint Neuro's stock. Their CLPT share price targets range from $9.00 to $15.00. On average, they predict the company's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 76.5% from the stock's current price.
View analysts price targets for CLPT
or view top-rated stocks among Wall Street analysts.

How have CLPT shares performed in 2024?

ClearPoint Neuro's stock was trading at $6.79 at the beginning of 2024. Since then, CLPT stock has increased by 0.1% and is now trading at $6.80.
View the best growth stocks for 2024 here
.

When is ClearPoint Neuro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CLPT earnings forecast
.

How were ClearPoint Neuro's earnings last quarter?

ClearPoint Neuro, Inc. (NASDAQ:CLPT) posted its earnings results on Tuesday, November, 9th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.02. The company had revenue of $4.57 million for the quarter. ClearPoint Neuro had a negative trailing twelve-month return on equity of 83.94% and a negative net margin of 92.21%. During the same quarter in the previous year, the firm posted ($0.09) earnings per share.

What guidance has ClearPoint Neuro issued on next quarter's earnings?

ClearPoint Neuro updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $28.0 million-$32.0 million, compared to the consensus revenue estimate of $30.4 million.

Who are ClearPoint Neuro's major shareholders?

ClearPoint Neuro's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.32%), Vanguard Group Inc. (5.30%), Cahill Wealth Management LLC (0.94%), Northern Trust Corp (0.80%), Lane Generational LLC (0.71%) and UBS Group AG (0.22%).
View institutional ownership trends
.

How do I buy shares of ClearPoint Neuro?

Shares of CLPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLPT) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners